TLR2 and neoplasm: Gijs et al. demonstrated that conjugation of new TLR2-L Amplivant (TLR2-ligand, a modified Pam3CSK4) to synthetic long peptides (SLPs) induced dendritic cells(DCs) maturation, T cell priming, and anti-tumor immunity strongly (Zom et al., 2018).